Results 141 to 150 of about 11,256 (207)

Liquid biopsy: a new window on the BRCA genes. [PDF]

ESMO Open
Incorvaia L, Gristina V, Pepe F, Bazan Russo TD, Santoni M, Mujacic C, Curigliano G, Malapelle U, Capoluongo ED, Russo A.   +9 more
europepmc   +1 more source

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors. [PDF]

Front Oncol
Ayoub MM, Osman SA, Alkarbi RM, Anjum R, Malki A.   +4 more
europepmc   +1 more source

PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. [PDF]

Front Cell Dev Biol
Ouhajjou A, Mazouji O, Nejjari C, Incitti R, Mansour H.   +4 more
europepmc   +1 more source

Platinum cross-resistance after first-line PARPi maintenance in ovarian cancer: a review and proposed redefinition of platinum resistance. [PDF]

Front Pharmacol
Mei R, Song L.
europepmc   +1 more source

Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review. [PDF]

Oncologist
Swearingen A, Audu B, Hamidu A, Mustapha A, Oguntayo A, Yahya A, Bello A, Butler R, Halliday D, Bowe S, Jordan S, Hew K, Pinto A, Castillo RP, Reis IM, George S, Schlumbrecht M.   +16 more
europepmc   +1 more source

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?

Gynecology & obstetrics (Sunnyvale, Calif.)
Peter G, Rose, Laura M, Chambers, Michelle, Kuznicki   +2 more
openaire   +1 more source

MTUS2-AS1 suppression promotes DDX5 protein degradation to enhance the sensitivity of PARP inhibitors in BRCA-wild triple negative breast cancer. [PDF]

Int J Biol Sci
Xu T, Nie J, Pan B, Hong Q, Fan Y, Dong L, Qin J, Sun H, Xu M, Pan Y, Wang S.   +10 more
europepmc   +1 more source

Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate Cancer. [PDF]

Cancers (Basel)
Gonzalez BC, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, Davis RR, Batra N, Lucchesi CA, Gao AC, Li H, McPherson JD, Dall'Era M, Lombard AP.   +13 more
europepmc   +1 more source

Shaping CDK4/6 Inhibitor Resistance: BRCA2 Germline Alterations Bias toward RB1 Inactivation. [PDF]

Cancer Res
Napolitano F, Hanker AB.
europepmc   +1 more source

Genome stability disrupted by the circRBM39(4,5,6)-RPA2 axis represses breast tumorigenesis. [PDF]

Proc Natl Acad Sci U S A
Bian X, Xu M, Li N, Sun C, Liu X, Deng Y, Liu D, Cao G, Lin W, Hong B, Shan G, Wang X.   +11 more
europepmc   +1 more source